MAM
Qibla Cola to attend UK Soft Drinks Industry Conference
MUMBAI: Qibla Cola Company Ltd, the UK based soft drink company, has been invited to speak at theUK Soft Drinks Industry Conference to be held on 6 May at the New Connaught Rooms in Central London.
The conference will address the role of soft drinks in society, with key speakers from major soft drinks companies including; Coca Cola, Pepsi and Britvic in attendance.
Qibla Cola has been asked to deliver a speech on the new cola agenda, confirms a press release.
“The Qibla Cola Company is here to provide all people of conscience with an alternate brand of popular soft drinks – a real alternative”, commented Qibla Cola chief communications officer Abid Hussain, who will be speaking at the conference.
He further added, “This is a hundred year old industry where change is required, continued social pressures and changing lifestyles will ensure an increase in choice. Qibla Cola is leading this change as the ethical choice for the consumer with a conscience.”
The conference will be attended by leading industry figures, and by the industry’s main customer groups.
MAM
Beacon Group appoints Dr Rajesh Patel as Group CEO
36-year healthcare veteran to lead Beacon Diagnostics, Vector Biotek, Biogeny.
MUMBAI: A new chief, a fresh diagnosis and a sharper prescription for growth. Beacon Group has appointed Dr Rajesh Patel as its Group Chief Executive Officer, effective April 1, 2026, signalling a decisive push to scale its presence in the diagnostics and IVD space. Patel steps into the role with 36 years of experience across the healthcare and diagnostics industry, bringing a career shaped by leadership roles spanning sales, marketing, business development and operational strategy. His mandate is both expansive and precise: to steer the group’s overall strategic direction while tightening coordination across its three core entities Beacon Diagnostics, Vector Biotek and Biogeny Diagnostics.
In practical terms, that means driving cross-company synergies, accelerating market expansion and strengthening organisational capability areas increasingly critical as diagnostic players compete for scale in a fragmented yet rapidly evolving healthcare ecosystem. The group is positioning itself to capture unmet demand across chain laboratories, key accounts and standalone labs, segments that remain underserved despite growing diagnostic needs.
The appointment comes at a time when the In Vitro Diagnostics (IVD) sector in India is entering a more competitive and innovation-led phase, with companies focusing not just on product pipelines but also on service delivery, integration and customer-centric models. Beacon’s leadership appears to be betting that Patel’s execution-focused approach can help translate ambition into operational momentum.
Welcoming the appointment, Chairman Dr D K Joshi described Patel’s induction as a strategic move aligned with the group’s long-term vision, emphasising the role of leadership depth in navigating the next phase of growth.
For Beacon Group, the message is clear, in a sector where precision matters, leadership is the new differentiator—and this appointment is intended to set the tone for what comes next.
